Drugs / Duobrii
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DUOBRII | — | 2019-04-25 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04119102 | Oct 2019 → Aug 2020 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT05282771 Comparator | Apr 2021 → Feb 2022 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duobrii | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05282771 ↗ |
| Known as | Halobetasol propionate and tazarotene lotion | “Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%” NCT05282771 ↗ |
| Route | Topical | “Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%” NCT05282771 ↗ |